Antibodies to β2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor

Thrombosis and Haemostasis

Volumn 84, Issue 4, 2000, Pages 653-656

  Salemink, I ^a   Blezer, R ^a   Willems, G M ^a   Galli, M ^a   Bevers, E ^a   Lindhout, T ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anti 2 glycoprotein I; FXa generation; TFPI; Tissue factor

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10A; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; AUTOANTIBODY; GLYCOPROTEIN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ADULT; AGED; ANTIBODY AFFINITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOSIS; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY;

ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; GLYCOPROTEINS; HUMANS; LIPOPROTEINS;

EID: 0033626575     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614082     Document Type: Article

References (27)

1. The tissue factor pathway: How it has become a 'primaballerina'
2. The role of tissue factor pathway inhibitor in a revised coagulation cascade
3. The importance of the binding of Factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: The transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor
4. Inhibition of tissue factor: Factor VIIa-catalyzed factor X activation by factor Xa: Tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition
5. Lupus anticoagulant antibodies: Recognition of phospholipid-binding protein complex
6. Thrombosis, abortion, cerebral disease and the lupus anticoagulant
7. Lupus anticoagulant, thrombosis and fetal loss
8. The lupus anticoagulant/antiphospholipid syndrome
9. The 1982 revised criteria for the classification of systemic lupus erythematosus
10. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantitation of results
11. Criteria for the diagnosis of lupus anticoagulant: An update
12. A sensitive assay of extrinsic pathway inhibitor (EPI) in plasma and plasma fractions
13. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: Induction of cooperativity by phosphatidylserine
14. 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles
15. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S
16. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli
17. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
18. 2-glycoprotein I complexes to lipid membranes
19. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma
20. 2-glycoprotein 1 of the factor Xa generating activity
21. In situ generated thrombin is the only enzyme that effectively activates factor VIII and Factor V in thromboplastin-activated plasma
22. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor
23. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor
24. 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies
25. 22-glycoprotein I antibodies with lupus anticoagulant activity
26. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes
27. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity